The company reported a loss on foreign currency exchange and net interest expense. Cash and cash equivalents decreased from the beginning to the end of the first quarter. The company was recently granted FDA approval for the investigational device exemption supplement for additional clinical trials for its dermaPACE.
More Articles on Orthopedic Devices:
14 Spine Devices Receive FDA 510(k) Clearance in April
MiMex Group Q1 Net Sales at $37M
US Spinal Implant Market to Reach $7B by 2018, Driven by Motion Preservation
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 18–20 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
